Smith+Nephew Ventures

Smith+Nephew Ventures is the strategic investment entity of Smith+Nephew, the global medical device company. Headquartered in Memphis, the corporate venture arm backs advanced orthopedic, sports medicine, and wound care prototypes. Its mandate aligns with the parent company’s three core franchises, meaning founders working on next-generation joint reconstruction, soft tissue repair, arthroscopic instruments, or chronic wound therapies fit the thesis. The fund operates as a corporate VC rather than a financial-only investor, meaning capital typically comes paired with strategic relevance to Smith+Nephew’s commercial pipeline and clinical channels.

The fund invests at Series A and Series B, with check sizes in the $1M to $5M range. While the parent operates globally, the venture entity is based in the United States. Investments are concentrated in medical devices and MedTech, with no stated AI focus. Founders should expect a corporate diligence process that weighs both clinical evidence and strategic fit against Smith+Nephew’s existing portfolio of orthopedic and wound management products.

Founders approaching Smith+Nephew Ventures should arrive with a clear regulatory pathway, meaningful clinical data or a credible plan to generate it, and a perspective on how the technology complements rather than cannibalizes existing product lines. Limited public information is available about specific portfolio companies or partner contacts, so warm introductions through orthopedic surgeons or sports medicine clinical advisors familiar with the company will likely be the most effective entry point.